The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -56,755 | -120,723 |
| Stock-based compensation | 5,980 | 16,489 |
| Loss on sale of property and equipment | - | -62 |
| Non-cash operating lease expense | 58 | 1,777 |
| Depreciation and amortization | 23 | 176 |
| Net accretion of investments in marketable securities | 612 | 2,185 |
| Impairment of held for sale assets | 0 | 378 |
| Non-cash interest expense and amortization of debt issuance costs | 213 | 303 |
| Other noncash expenses | 39 | - |
| Prepaid expenses and other current assets | 326 | -1,111 |
| Accounts payable | -96 | -2,663 |
| Accrued liabilities | 4,865 | -4,650 |
| Operating lease liabilities | 39 | -1,873 |
| Other assets | -1 | 54 |
| Net cash used in operating activities | -46,633 | -111,852 |
| Purchases of marketable securities | 0 | 82,868 |
| Cash paid for acquisition of assets | 0 | 0 |
| Proceeds from maturities of marketable securities | 51,246 | 157,341 |
| Proceeds from sale of property and equipment | 87 | 84 |
| Purchases of property and equipment | 16 | - |
| Net cash provided by investing activities | 51,317 | 74,557 |
| Net proceeds from term loan | -136 | 18,398 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from employee stock purchase plan purchases | 0 | 59 |
| Payments for offering costs in connection with at-the-market offering and initial public offering | 0 | - |
| Net cash provided by financing activities | -136 | 18,457 |
| Net change in cash and cash equivalents and restricted cash | 4,548 | -18,838 |
| Cash and cash equivalents at beginning of period | 143,361 | - |
| Cash and cash equivalents at end of period | 129,071 | - |
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)